After a record year for NASDAQ listings, a burgeoning queue of biopharmas seeking IPOs in 2021 swelled further late Tuesday as immuno-oncology companies Adagene and NexImmune filed for offerings. The pair joined seven therapeutics developers...

With two biopharmas already trading on NASDAQ following their IPOs this month, the queue of companies seeking public listings has begun to swell. Seven therapeutics developers filed for offerings late Friday, ready to test investors’...

While it’s too early to say whether 2020’s record year of fund-raising constitutes a “new normal,” there’s consensus among buysiders and bankers that a cheap money environment will continue in 2021 as...

IO Biotech parlayed early clinical data into a €127 million ($154.8 million) series B financing led by HBM Healthcare Investments, which will support a Phase II trial of its leading cancer vaccines in combination with...

With its IPO filing Wednesday, well-funded start-up Sana has lifted the lid on a suite of technologies it has aggregated since 2018, giving it a pipeline of 11 cell and gene therapies. Its first INDs...

The Asklepios BioPharmaceutical Inc. (AskBio) unit of Bayer AG (Xetra:BAYN) hired Spark Therapeutics Inc. alum Katherine High as president, therapeutics. As president and head of R&D at Spark, High led the development and regulatory approval of Luxturna...

Gracell has followed fellow CAR T companies Legend, Allogene and bluebird onto NASDAQ with an oversubscribed IPO that the Suzhou company hopes will help put it on the map as a global player in the space....

After a quiet first nine months, Paris-based VC Jeito ended 2020 with a trio of investments and a €50 million infusion by Sanofi. And while all three venture plays were in early-stage gene and cell...

Life sciences stocks continued an upward trajectory at the end of 2020, with median gains of at least 7% in 4Q20 and at least 24% over the year across all market cap tiers. Companies valued...

The pandemic has only deepened the already heavily-weighted oncology focus of many portfolios, and it’s targeted oncology opportunities that are catching the eyes of buysiders in 2021. A combination of...